This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2004 Sep 16;351(12):1260-1; author reply 1260-1.

EGFR mutations and sensitivity to gefitinib

Jeremy N Rich, B K Ahmed Rasheed, Hai Yan

PMID: 15376352

Comment

EGFR mutations and sensitivity to gefitinib

Jeremy N Rich et al. N Engl J Med. 2004.

. 2004 Sep 16;351(12):1260-1; author reply 1260-1.

Authors

Jeremy N Rich, B K Ahmed Rasheed, Hai Yan

PMID: 15376352

No abstract available

PubMed Disclaimer

Comment on

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Lynch TJ, et al. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29. N Engl J Med. 2004. PMID: 15118073

Similar articles

EGFR mutations and sensitivity to gefitinib.
Rossi G, Marchioni A, Longo L. Rossi G, et al. N Engl J Med. 2004 Sep 16;351(12):1260-1; author reply 1260-1. N Engl J Med. 2004. PMID: 15376351 No abstract available.
Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.
Taja-Chayeb L, Candelaria M, Brom R, Trejo-Becerril C, Meza F, Duenas-Gonzalez A. Taja-Chayeb L, et al. Lung Cancer. 2005 Nov;50(2):259-63. doi: 10.1016/j.lungcan.2005.05.015. Epub 2005 Jul 11. Lung Cancer. 2005. PMID: 16009451
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K. Takeda M, et al. Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28. Jpn J Clin Oncol. 2012. PMID: 22457323
[Mutations in the epidermal growth factor receptor: structure and biological function in human tumors].
Pedersen MW, Poulsen HS. Pedersen MW, et al. Ugeskr Laeger. 2006 Jun 12;168(24):2354-61. Ugeskr Laeger. 2006. PMID: 16822420 Review. Danish.
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T. Gridelli C, et al. Lung Cancer. 2011 Mar;71(3):249-57. doi: 10.1016/j.lungcan.2010.12.008. Epub 2011 Jan 8. Lung Cancer. 2011. PMID: 21216486 Review.

See all similar articles

Cited by

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.
de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. de Groot JF, et al. J Neurooncol. 2008 Oct;90(1):89-97. doi: 10.1007/s11060-008-9637-y. Epub 2008 Jun 26. J Neurooncol. 2008. PMID: 18581057 Free PMC article. Clinical Trial.
Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma.
Toth J, Egervari K, Klekner A, Bognar L, Szanto J, Nemes Z, Szollosi Z. Toth J, et al. Pathol Oncol Res. 2009 Jun;15(2):225-9. doi: 10.1007/s12253-008-9082-4. Epub 2008 Aug 28. Pathol Oncol Res. 2009. PMID: 18752056
Osimertinib induces paraptosis and TRIP13 confers resistance in glioblastoma cells.
Hu L, Shi J, Shen D, Zhai X, Liang D, Wang J, Xie C, Xia Z, Cui J, Liu F, Du S, Meng S, Piao H. Hu L, et al. Cell Death Discov. 2023 Sep 5;9(1):333. doi: 10.1038/s41420-023-01632-6. Cell Death Discov. 2023. PMID: 37669963 Free PMC article.
Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives.
Ronellenfitsch MW, Steinbach JP, Wick W. Ronellenfitsch MW, et al. Target Oncol. 2010 Sep;5(3):183-91. doi: 10.1007/s11523-010-0154-5. Epub 2010 Sep 19. Target Oncol. 2010. PMID: 20853178 Review.
Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
Taylor TE, Furnari FB, Cavenee WK. Taylor TE, et al. Curr Cancer Drug Targets. 2012 Mar;12(3):197-209. doi: 10.2174/156800912799277557. Curr Cancer Drug Targets. 2012. PMID: 22268382 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal